The continuing search for effective treatments for older adults with acute myeloid leukemia

Over the last 5 years, the landscape of AML therapy in older patients with AML has moved from uniform approaches toward more personalized therapy based on molecularly defined subtypes that benefit from target-directed therapy. Favorable results obtained with the synergistic combination venetoclax/HMA are currently opening a new active treatment research era by adding other specific drugs to this backbone regimen.